keep in mind that these were very hard to treat patients and the trial design limited the power of the study (small sample size). A key pint to the press release for me is the following;
At 4 weeks, the proportion of responders on MultiStem was significantly greater than placebo but the benefit was offset by declines in a minority of MultiStem-treated patients such that overall benefit at all time points measured was not significant.
So, we have a few patients skewing the statistics. If the study included a greater sample size the skewing would be better controlled. We won't know for sure until we see the full data set.
I would not discount the other programs....I'm buying today.
Market Data 
Markets 
AI
